Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 June 2023 | Story Nonsindiso Qwabe | Photo Supplied
UFS Qwaqwa Campus Africa Day
The UFS Qwaqwa Campus Africa Day event celebrates African heritage and diversity.

The University of the Free State (UFS) Qwaqwa Campus concluded Africa Month with a multicultural array of performances at their Africa Day Celebration event on 27 May 2023.

The Qwaqwa Campus is renowned for its traditional flair, and each of the 17 performers captivated the audience with cultural ingenuity, creating an atmosphere of excitement and energy in the campus’ Mandela Hall. Students came together to honour Africa’s rich cultural heritage through traditional music, dance, poetry, cuisine, and fashion. The Department of Student Affairs and the Office for International Affairs collaborated to make the celebrations a resounding success.

According to the campus’ Student Life Senior Officer, Simbongile Jojo, the event served a greater purpose beyond artistic expression. “The celebration allowed students to share their rich cultures and heritage. It also encouraged students to take an interest in expanding their knowledge of other cultures, fostering a sense of multicultural solidarity and unity.”

Celebrating and embracing cultures outside one’s own

In addition to the music, dance, and spoken word, external fashion designers were given a platform to showcase their garments, adding an extra flair to diversity and artistic expression.

The Director of Student Affairs on the campus, Zoleka Dotwana, said her division prioritised student cohesion and celebrating and embracing cultures outside their own. “What a fantastic arts and culture event. Amid the freezing weather conditions, I haven’t seen such enthusiasm and social cohesion among students since the first-year welcoming week. The event was about celebrating Africa as a collective of citizens from various corners and doing so with pride. Our partnership with the International Office came in handy as well. I would like to highlight that Qwaqwa students are exceptionally talented. How I wished we had more time for them to enjoy themselves.

The Qwaqwa Campus introduced colleges for on- and off-campus students in 2023, and Dotwana said the model was already bearing fruit in bringing the student community together. “It was encouraging to see the participation of off-campus students and witness how proud students were in parading their cultures. I was surprised to find out that we have Tsonga students on the campus.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept